Health Care Supplies

LIFERIVER

LIFERIVER released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 25.42 M, actual EPS CNY -0.15

LIFERIVER to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

LIFERIVER FY2025 Annual Earnings Release on April 24, 2026 Pre-Market (BJT)

LIFERIVER 于 2026 年 2 月 27 日盘前 (北京时间) 发布 FY2025 年报，实际营收 124.82 M CNY，实际 EPS -0.19 CNY

LIFERIVER 于 2026 年 2 月 27 日盘前 (北京时间) 发布 FY2025 Q4 业绩，实际营收 34.39M CNY，实际 EPS -0.0287 CNY

LIFERIVER released FY2025 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 90.43 M, actual EPS CNY -0.1727

LIFERIVER released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 30.75 M, actual EPS CNY -0.1245

LIFERIVER to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

LIFERIVER released FY2025 Q2 earnings on August 28 During-Market (BJT), actual revenue CNY 27.55 M, actual EPS CNY 0.0318

LIFERIVER released FY2025 Semi-Annual Earnings on August 28 During-Market (BJT), Actual Revenue: CNY 59.68 M, Actual EPS: CNY -0.05

LIFERIVER to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Zhejiang Bio Seven Nucleic Acid Extraction Reagent Products Obtained Netherlands Certification

Zhejiang Bio 积极推进 Japanese Project 审批

Zhejiang BioTech Plans to Repurchase Shares for 60 to 120 Million Yuan

Zhejiang Bio's 2025 Q1 Report Shows Significant Decline in Main Business Revenue and Net Profit

LIFERIVER released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 32.13 M, actual EPS CNY -0.08

Zhejiang Bio Not to Distribute Profits in 2024

LIFERIVER to Release FY2025 Q1 Earnings on April 30 After-Market BJT

LIFERIVER FY2024 Annual Earnings Release Scheduled for April 25, 2025, After-Market BJT

Zhijiang Biology Repurchases Approximately 6 Million Shares, Total Buyback Amount Reaches 102 Million Yuan

688317

002022

301080

300639

300482

688399

688298

002030

300463

The A-share biopharmaceutical sector continues to strengthen, with Maccura, Hybribio Biotech, and KHB hitting the daily limit up in the afternoon. LIFERIVER and DAJY had previously reached their limit up, while WONDFO BIOTECH, ACROBIOSYSTEMS, Orient Biotech, and SSSW rose over 10%

Wallstreetcn

ACROBIOSYSTEMS

Hybribio Biotech

WONDFO BIOTECH

SSSW

Orient Biotech

DAJY

maccura

According to the Zhitong Finance APP, LIFERIVER announced that one of its products recently obtained the national Class III medical device registration certificate, with the product name: Novel Coronavirus 2019-nCoV Nucleic Acid Detection Kit (Fluorescent PCR Method)

Zhitong

LIFERIVER obtained a medical device registration certificate

According to the Zhitong Finance APP, LIFERIVER disclosed its third-quarter report for 2025, stating that the company's revenue for the first three quarters was 90.43 million yuan, a year-on-year decrease of 34.27%; the net profit attributable to the parent company was a loss of 29.38 million yuan; the net profit excluding non-recurring gains and losses was a loss of 37.25 million yuan; basic earnings per share were -0.16 yuan

LIFERIVER released its performance for the first three quarters, with a net loss attributable to the parent company of 29.38 million yuan

LIFERIVER announced that the company plans to repurchase a portion of its issued ordinary shares through centralized bidding, with the repurchase amount not less than 60 million yuan and not exceeding 120 million yuan. The funding sources will be from its own funds and special loans for stock repurchase. The repurchase price will not exceed 37.99 yuan per share, and the repurchased shares are intended for the employee stock ownership plan or equity incentives

LIFERIVER: Plans to repurchase shares for 60 million to 120 million yuan

LIFERIVER announced that its monkeypox virus nucleic acid detection kit (fluorescent PCR method) has been included in the World Health Organization's Emergency Use Listing, effective September 17, 2025. This recognition will support the company's promotion and sales in overseas markets

LIFERIVER: Monkeypox virus nucleic acid testing kit (fluorescent PCR method) included in WHO emergency use list

LIFERIVER stated on the interactive platform that the company has established a product line for the detection of mosquito-borne infectious diseases, covering chikungunya virus, dengue virus, Zika virus, etc., compatible with fully automated molecular testing equipment, serving scenarios such as disease control centers, port quarantine, and third-party laboratories. For the chikungunya virus, the company has developed multiple testing kits that can be used for suspected case screening, close contact monitoring, and large-scale screening

LIFERIVER: Has established a product line for the detection of mosquito-borne infectious diseases, including the Chikungunya virus

002370

300642

The monkeypox concept has seen a surge, with KHB hitting the limit up, and DAJY, Yatai pharm, Lanwei Medical, WONDFO BIOTECH, Tellgen, and LIFERIVER also rising

Yatai pharm

Tellgen

Monkeypox concept stocks surged, KHB hit the limit up

According to the Zhitong Finance APP, LIFERIVER announced that the company recently received relevant certifications from the Dutch authorities for 7 products, all of which are nucleic acid extraction reagents

LIFERIVER has obtained relevant certifications for multiple products

LIFERIVER announced that the operating revenue for 2024 is expected to be 179 million yuan, a year-on-year decrease of 34.88%. The net loss attributable to shareholders of the listed company is 127 million yuan, compared to 137 million yuan in the same period last year. The company has decided not to distribute profits for the year 2024, will not issue cash dividends, and will not engage in other forms of profit distribution. This profit distribution plan needs to be submitted to the 2024 annual general meeting of shareholders for review

LIFERIVER: Net loss of 127 million yuan in 2024

As of April 7, 2025, LIFERIVER has repurchased approximately 6 million shares through centralized bidding, accounting for 3.12% of the total share capital. This repurchase has increased by 0.43% compared to the last disclosure, with repurchase prices ranging from 15.25 yuan to 17.88 yuan, totaling an expenditure of 102 million yuan (excluding transaction fees)

LIFERIVER has repurchased 3.12% of its shares at a cost of 102 million yuan

LIFERIVER(688317.SH)